Skip to main content
Erschienen in: International Journal of Clinical Oncology 1/2018

24.08.2017 | Introduction to Invited Review Articles

Hereditary breast cancer: molecular biology and management update

verfasst von: Hiroko Yamashita

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

For BRCA1 and BRCA2 carriers, lifetime estimates of breast cancer risk range from 49% to 88%, whereas the risk of ovarian cancer ranges from 40% to 59%, and from 18% to 35%, for BRCA1 or BRCA2 carriers, respectively [1, 2]. Approximately 5% of unselected patients with breast cancer carry a germline BRCA mutation. The identification of BRCA1 and BRCA2 mutations permits the implementation of prevention strategies, including screening by magnetic resonance imaging or risk-reducing surgeries. As tumor suppressor genes, BRCA1 and BRCA2 encode proteins involved in the repair of DNA double-strand breaks by way of a homologous recombination repair pathway. Members of the poly (ADP-ribose) polymerase (PARP) family of enzymes are central to the repair of DNA single-strand breaks. Consequently, the oral PARP inhibitor, olaparib, is approved for the treatment of patients with recurrent ovarian cancer and a BRCA mutation. Moreover, olaparib has also been shown to have significant benefits compared with standard therapy in patients with metastatic breast cancer and a germline BRCA mutation [3]. In addition, since the initial discovery that pathogenic germline alterations in BRCA1 and BRCA2 genes increase susceptibility to breast and ovarian cancers, many genes have subsequently been discovered that also increase breast cancer risk [4]. Advances in technology have resulted in the ability to test for multiple genes associated with a hereditary predisposition to breast cancer. …
Literatur
2.
Zurück zum Zitat van der Kolk DM, de Bock GH, Leegte BK et al (2010) Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 124:643–651CrossRefPubMed van der Kolk DM, de Bock GH, Leegte BK et al (2010) Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 124:643–651CrossRefPubMed
3.
Zurück zum Zitat Robson M, Im SA, Senkus E et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523–533CrossRefPubMed Robson M, Im SA, Senkus E et al (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523–533CrossRefPubMed
4.
Zurück zum Zitat Nielsen FC, van Overeem Hansen T, Sorensen CS (2016) Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer 16:599–612CrossRefPubMed Nielsen FC, van Overeem Hansen T, Sorensen CS (2016) Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer 16:599–612CrossRefPubMed
5.
Zurück zum Zitat Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71CrossRefPubMed Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71CrossRefPubMed
Metadaten
Titel
Hereditary breast cancer: molecular biology and management update
verfasst von
Hiroko Yamashita
Publikationsdatum
24.08.2017
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 1/2018
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-017-1183-1

Weitere Artikel der Ausgabe 1/2018

International Journal of Clinical Oncology 1/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.